Incyte (NASDAQ:INCY) reports that a Phase 3 clinical trial, GRAVITAS-301 evaluating the combination of JAK1 inhibitor itacitinib and corticosteroids in patients with treatment-naïve acute graft-versus-host disease (GvHD) did not meet the primary endpoint of a statistically significant improvement in overall response rate (ORR) at Day 28 compared to placebo plus corticosteroids (74.0 percent vs. 66.4 percent, p=0.08, respectively).
There was also no difference in non-relapse mortality at month 6, a key secondary endpoint.
Results will be submitted for presentation at a future medical conference.
Management will host a conference call today at 5:00 pm ET to discuss the data.
Shares down 10% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.